Alison J Scott1, Benjamin L Oyler2, David R Goodlett3, Robert K Ernst4. 1. Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, United States. 2. Institute of Marine & Environmental Technology, University of Maryland Center for Environmental Science, Baltimore, MD 21202, United States. 3. Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, United States. 4. Department of Microbial Pathogenesis, School of Dentistry, University of Maryland, Baltimore, MD 21201, United States. Electronic address: rkernst@umaryland.edu.
Abstract
Strategies utilizing Toll-like receptor 4 (TLR4) agonists for treatment of cancer, infectious diseases, and other targets report promising results. Potent TLR4 antagonists are also gaining attention as therapeutic leads. Though some principles for TLR4 modulation by lipid A have been described, a thorough understanding of the structure-activity relationship (SAR) is lacking. Only through a complete definition of lipid A-TLR4 SAR is it possible to predict TLR4 signaling effects of discrete lipid A structures, rendering them more pharmacologically relevant. A limited 'toolbox' of lipid A-modifying enzymes has been defined and is largely composed of enzymes from mesophile human and zoonotic pathogens. Expansion of this 'toolbox' will result from extending the search into lipid A biosynthesis and modification by bacteria living at the extremes. Here, we review the fundamentals of lipid A structure, advances in lipid A uses in TLR4 modulation, and the search for novel lipid A-modifying systems in extremophile bacteria. This article is part of a Special Issue entitled: Bacterial Lipids edited by Russell E. Bishop.
Strategies utilizing pan class="Gene">Toll-like receptor 4 (ecies">pan class="Gene">TLR4) agonists for treatment of cancer, infectious diseases, and other targets report promising results. Potent TLR4 antagonists are also gaining attention as therapeutic leads. Though some principles for TLR4 modulation by lipid A have been described, a thorough understanding of the structure-activity relationship (SAR) is lacking. Only through a complete definition of lipid A-TLR4 SAR is it possible to predict TLR4 signaling effects of discrete lipid A structures, rendering them more pharmacologically relevant. A limited 'toolbox' of lipid A-modifying enzymes has been defined and is largely composed of enzymes from mesophile human and zoonotic pathogens. Expansion of this 'toolbox' will result from extending the search into lipid A biosynthesis and modification by bacteria living at the extremes. Here, we review the fundamentals of lipid A structure, advances in lipid A uses in TLR4 modulation, and the search for novel lipid A-modifying systems in extremophile bacteria. This article is part of a Special Issue entitled: Bacterial Lipids edited by Russell E. Bishop.
Authors: Christopher Huggins; Stuart Pearce; Francesco Peri; Frank Neumann; Gillian Cockerill; Grisha Pirianov Journal: Atherosclerosis Date: 2015-08-08 Impact factor: 5.162
Authors: Jean-Philippe Michaud; Maxime Hallé; Antoine Lampron; Peter Thériault; Paul Préfontaine; Mohammed Filali; Pascale Tribout-Jover; Anne-Marie Lanteigne; Rachel Jodoin; Christopher Cluff; Vincent Brichard; Rémi Palmantier; Anthony Pilorget; Daniel Larocque; Serge Rivest Journal: Proc Natl Acad Sci U S A Date: 2013-01-15 Impact factor: 11.205
Authors: Adeline M Hajjar; Robert K Ernst; Edgardo S Fortuno; Alicia S Brasfield; Cathy S Yam; Lindsay A Newlon; Tobias R Kollmann; Samuel I Miller; Christopher B Wilson Journal: PLoS Pathog Date: 2012-10-11 Impact factor: 6.823
Authors: Sara Carillo; Giuseppina Pieretti; Buko Lindner; Ida Romano; Barbara Nicolaus; Rosa Lanzetta; Michelangelo Parrilli; Maria Michela Corsaro Journal: Mar Drugs Date: 2013-01-21 Impact factor: 5.118
Authors: Benjamin L Oyler; Mohd M Khan; Donald F Smith; Erin M Harberts; David P A Kilgour; Robert K Ernst; Alan S Cross; David R Goodlett Journal: J Am Soc Mass Spectrom Date: 2018-02-20 Impact factor: 3.109
Authors: Erin M Harberts; Daniel Grubaugh; Daniel C Akuma; Sunny Shin; Robert K Ernst; Igor E Brodsky Journal: Infect Immun Date: 2022-07-14 Impact factor: 3.609
Authors: Alison J Scott; Julia Maria Post; Raissa Lerner; Shane R Ellis; Joshua Lieberman; Kari Ann Shirey; Ron M A Heeren; Laura Bindila; Robert K Ernst Journal: Proc Natl Acad Sci U S A Date: 2017-11-06 Impact factor: 11.205
Authors: Kelsey A Gregg; Erin Harberts; Francesca M Gardner; Mark R Pelletier; Corinne Cayatte; Li Yu; Michael P McCarthy; Jason D Marshall; Robert K Ernst Journal: Vaccine Date: 2018-05-31 Impact factor: 3.641
Authors: Hyojik Yang; Courtney E Chandler; Shelley N Jackson; Amina S Woods; David R Goodlett; Robert K Ernst; Alison J Scott Journal: Anal Chem Date: 2020-09-28 Impact factor: 6.986
Authors: Anna E Gauthier; Courtney E Chandler; Valentina Poli; Francesca M Gardner; Aranteiti Tekiau; Richard Smith; Kevin S Bonham; Erik E Cordes; Timothy M Shank; Ivan Zanoni; David R Goodlett; Steven J Biller; Robert K Ernst; Randi D Rotjan; Jonathan C Kagan Journal: Sci Immunol Date: 2021-03-12
Authors: Anne E Mattingly; Karlie E Cox; Richard Smith; Roberta J Melander; Robert K Ernst; Christian Melander Journal: ACS Infect Dis Date: 2020-09-11 Impact factor: 5.084